Tango Therapeutics (TNGX) furnishes Q3 2025 results press release

Tango Therapeutics (TNGX) furnished a press release covering its results of operations and financial condition for the quarter ended September 30, 2025, via an Item 2.02 Form 8‑K. The press release is furnished, not filed, and appears as Exhibit 99.1.

Rhea-AI Filing Summary

Tango Therapeutics (TNGX) furnished a press release covering its results of operations and financial condition for the quarter ended September 30, 2025, via an Item 2.02 Form 8‑K.

The press release is furnished, not filed, and appears as Exhibit 99.1. The report was signed by Chief Financial Officer Daniella Beckman.

8-K Event Classification

Item 2.02 — Results of Operations and Financial Condition

1 item

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Tango Therapeutics (TNGX) announce in this 8-K?

Tango furnished a press release with results of operations and financial condition for the quarter ended September 30, 2025.

Under which item was the information provided?

The information was furnished under Item 2.02 (Results of Operations and Financial Condition).

Is the press release deemed filed for liability purposes?

No. It is furnished, not filed, and is not subject to Section 18 liabilities.

Where can the press release be found within the filing?

It is included as Exhibit 99.1.

Who signed the report for Tango Therapeutics?

Chief Financial Officer Daniella Beckman.

What period does the press release cover?

It covers the quarter ended September 30, 2025.

What is the trading symbol and exchange for Tango Therapeutics?

The trading symbol is TNGX on The Nasdaq Global Market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/04/2025 - 09:10 AM EST Learn about SEC filing dates

false000181913300018191332022-08-102022-08-10

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGEACT OF 1934

Date of Report (Date of earliest event reported): November 4, 2025

TANGO THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-39485	85-1195036
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

201 Brookline Ave., Suite 901 Boston, MA	02215
(Address of principal executive offices)	(Zip code)

Registrant’s telephone number, including area code: 857-320-4900

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b)under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c)under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.001 per share		TNGX		The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 4, 2025, Tango Therapeutics, Inc. (“Tango” or the “Company”) issued a press release relating to its results of operations and financial condition for the quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The press release, and the information set forth therein (including Exhibit 99.1), is being furnished pursuant to Item 2.02 of this Current Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section. Nor shall such document be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in the filing unless specifically stated so therein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description

99.1 Press Release issued by Tango Therapeutics, Inc. on November 4, 2025 relating to its results of operations and financial condition for the quarter ended September 30, 2025.

104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TANGO THERAPEUTICS, INC.

Dated: November 4, 2025 By: /s/ Daniella Beckman

Name: Daniella Beckman

Title: Chief Financial Officer